Although the development of tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 has significantly revolutionized the treatment of CML, resistance to TKIs eventually occurs in a portion of CML patients, leading to therapy failure and further progression of CML3. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.